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A	country’s	research	success	can	be	assessed	from	the	power	law	function	that	links	country	
and	world	rank	numbers	when	publications	are	ordered	by	their	number	of	citations;	a	
similar	function	describes	the	distribution	of	country	papers	in	world	percentiles.	These	
functions	allow	calculating	a	country’s	probability	of	publishing	highly	cited	papers,	which	
can	be	used	as	an	indicator	of	the	country’s	probability	of	achieving	important	discoveries	or	
scientific	breakthroughs.	The	aim	of	this	paper	was	to	use	this	probability	and	other	
parameters	derived	from	the	percentile-based	power	law	function	to	investigate	research	
success	in	the	USA,	the	EU,	and	other	countries	in	hot	medical,	biochemical,	and	
biotechnological	topics.	The	results	show	that,	in	the	investigated	fields,	the	USA	is	
scientifically	ahead	of	all	countries	and	that	its	research	is	likely	to	produce	approximately	
80%	of	the	important	global	breakthroughs	in	the	research	topics	investigated	in	this	study.	
EU	research	has	maintained	a	constant	weak	position	with	reference	to	USA	research	over	
the	last	30	years.	
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1.	Introduction	
	
Countries	and	institutions	require	reliable	research	assessment	methods	to	determine	the	
profitability	of	their	research	investments.	In	the	absence	of	reliable	research	assessments,	
the	actual	economic	and	societal	benefits	of	research	and	its	contribution	to	the	progress	of	
knowledge	cannot	be	judged.	Research	produces	knowledge	and,	in	most	cases,	this	
knowledge	is	used	by	other	systems	to	produce	economic	and	other	societal	benefits	
(Bornmann	&	Marx,	2014);	however,	the	production	of	knowledge	depends	on	the	
breakthrough	potential	of	the	research	system	and	is	not	proportional	to	the	amount	of	R&D	
investment	and	capital	as	assumed	in	most	econometric	analyses	(Rodríguez-Navarro	&	
Brito,	2018b).	The	inaccuracy	of	this	assumption	explains	that,	although	the	economic	
benefits	of	research	are	generally	widely	accepted,	“no	simple	model	of	the	nature	of	the	
economic	benefits	from	basic	research	is	possible”	(Salter	&	Martin,	2001,	p.	527).	
Consequently,	in	the	absence	of	accurate	assessments,	the	low	benefits	of	research	in	lowly	
performing	research	systems	could	be	assumed	to	occur	because	the	benefits	of	research	
are	intrinsically	low.	This	conclusion	could	lead	to	the	political	response	of	decreasing	
research	funding	instead	of	improving	research	performance.	
	
Although	evaluating	the	performance	of	research	systems	in	terms	of	knowledge	production	
is	highly	required,	many	issues	make	it	difficult.	Within	the	scope	of	this	study,	the	most	
important	issue	is	the	intangible	nature	of	knowledge	progress	(Martin	&	Irvine,	1983),	
which	is	the	product	that	should	be	measured.	Publications	are	tangible	and	counting	them	
is	widely	used	in	research	assessments	as	a	substitute	for	measuring	knowledge	production.	
However,	this	substitution	is	formally	incorrect	as	some	publications	are	unnecessary	and	
others	report	data	that	are	interesting	for	researchers	but	irrelevant	for	society	at	large.	In	
fact,	the	publications	that	report	discoveries	and	breakthroughs	are	a	small	amount,	but	are	
supported	by	a	large	number	of	“normal	publications,”	adopting	a	Kuhnian	terminology	
(Kuhn,	1970).	In	the	end,	the	ratio	between	the	number	of	scientific	publications	that	report	
discoveries	or	breakthroughs	and	the	total	number	of	publications	is	very	low	(Rodríguez-
Navarro,	2012)	and	is	expected	to	vary	across	countries.	Therefore,	assessing	the	share	of	
breakthrough	publications	by	countries	and	institutions	is	impossible	through	the	counting	
of	these	publications;	for	example,	if	a	research	field	with	100,000	annual	publications	
produces	only	20–30	real	discoveries	or	breakthroughs,	it	will	take	most	small	countries	or	
institutions	several	years	to	produce	one	of	them.	Therefore,	counting	publications,	either	
the	total	number	or	those	reporting	breakthroughs,	cannot	be	methods	of	research	
assessment.	In	contrast,	a	likely	solution	to	this	conundrum	would	be	to	calculate	the	
cumulative	probability	of	producing	breakthrough	publications.	Multiplying	this	probability	
by	the	total	number	of	publications	produces	the	cumulative	frequency	of	breakthrough	
publications	for	a	country	or	institution,	which,	as	already	mentioned,	may	be	much	lower	
than	one	per	year.	
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This	evaluation	procedure	based	on	a	mathematical	probability	is	possible	by	utilizing	the	
percentile-based	double	rank	approach,	which	uses	the	total	number	of	papers	to	construct	
the	cumulative	probability	distribution	and	estimates	the	chance	of	a	breakthrough	
discovery	(Brito	&	Rodríguez-Navarro,	2018).	In	addition	to	the	probability	of	achieving	a	
breakthrough,	another	basic	parameter	obtained	using	this	approach	is	the	ep	index,	which	
reveals	the	intrinsic	properties	of	the	distribution	of	country	publications	among	global	
publications	(Rodríguez-Navarro	&	Brito,	2018b).	The	ep	index	increases	or	decreases	
depending	on	whether	the	frequency	of	country	publications	among	global	publications	
increases	or	decreases	when	going	up	the	citation	scale.	A	uniform	distribution	implies	
identity	with	the	world	average	and	an	ep	index	value	of	0.10.	
	
In	a	previous	study,	this	approach	was	used	to	assess	the	performance	of	technological	
research	in	three	world	geographical	areas:	the	USA,	the	EU,	and	the	rest	of	the	world	
(Rodríguez-Navarro	&	Brito,	2018b).	The	results	showed	that	the	USA	and	some	non-USA,	
non-EU	countries	dominate	at	similar	levels	the	global	production	of	breakthrough	papers	in	
fast	evolving	research	topics	while	the	EU	lags	far	behind.	In	slow	evolving	technological	
topics	research	is	dominated	by	non-USA,	non-EU	countries	and	the	USA	and	the	EU	lag	
slightly	behind.	However,	this	study	only	considered	physical-	and	chemical-based	
technologies.	Although	these	technologies	support	a	large	proportion	of	economic	growth,	
two	other	research	fields,	namely	medicine	and	biotechnology,	have	a	large	societal	
relevance.	Therefore,	the	present	study	is	focused	on	these	important	research	areas.	
	
In	section	3.1	we	describe	research	performance	in	hot	medical	topics	and	a	similar	study	in	
biochemistry	and	biotechnology	is	presented	in	section	3.2.	A	general	discussion	of	the	
findings	is	presented	in	section	4.	
	
2.	Previous	considerations	and	methods	
	
2.1.	Research	performance	parameters	
	
As	in	previous	studies,	we	assume	that	the	ep	index	and	the	probability	of	publishing	very	
highly	cited	papers	are	indicators	of	the	breakthrough	potential	of	a	country	(Rodríguez-
Navarro	&	Brito,	2018b).	Therefore,	using	the	percentile-base	double	rank	approach	we	
calculated	three	evaluation	parameters	for	each	country	or	group	of	countries:	the	ep	index,	
the	probability	that	a	country	or	institution’s	publication	has	to	reach	the	top	0.01	citation	
percentile,	and	the	cumulative	frequency	of	publications	in	this	percentile.	
	
The	calculation	of	these	parameters	was	described	previously	(Rodríguez-Navarro	&	Brito,	
2018b).	Briefly,	global	and	country	publications	were	ranked	in	parallel	using	the	number	of	
citations	in	decreasing	order;	the	percentile	limits	in	the	global	list	(any	percentile	from	1%	
to	100%)	were	fixed	in	according	to	the	rank	numbers	and	turned	into	the	number	of	
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citations	of	the	last	paper	of	the	selected	percentile.	Then,	the	country	number	of	
publications	in	each	selected	percentile	was	equal	to	the	number	of	papers	with	the	same	or	
higher	number	of	citations	as	the	last	paper	of	the	selected	percentile	in	the	global	list	(i.e.,	
the	country	ranking	number	of	the	last	paper).	When	in	the	global	and	country	lists	the	
percentile	limits	occurred	in	sets	of	publications	with	the	same	number	of	citations	
(Waltman	&	Schreiber,	2013),	the	number	of	tied	publications	in	the	country	set	was	fixed	
using	a	proportional	method	(i.e.,	proportional	number	of	tied	publications	in	global	and	
country	lists).	This	method	is	very	accurate	and	can	be	used	for	those	researches	than	
cannot	download	hundreds	of	thousands	of	publications.	Figure	1	shows	the	accuracy	of	this	
method	in	biological	areas,	which	is	similar	to	that	found	in	technological	areas	(Figure	1	in	
Rodríguez-Navarro	&	Brito,	2018b).	
	
	
Figure	1.	Cumulative	probability	plots	for	a	paper	from	the	USA	and	the	EU	excluding	the	UK	to	reach	a	specific	
top	percentile.	Publications	in	2014	relating	to	a)	top	medical	topics	and	b)	biochemical	and	biotechnological	
research	areas.	
	
After	counting	the	number	of	publications	in	a	series	of	percentiles,	N(x),	the	percentile	
distribution	of	the	number	of	publications	(i.e.,	cumulative	frequencies)	was	fitted	to	a	
power	law	as	shown	in	Figure	1.	The	ep	index,	which	is	defined	as	the	N(1)/N(10)	ratio,	is	also	
equal	to	10	raised	to	minus	the	exponent	of	the	fitted	power	law	function	(Rodríguez-
Navarro	&	Brito,	2018b).	The	equations	are:	
	
	 	 	 	 	 𝑁 𝑥 	=	𝑁	 $%&& ' 	 	 	 	 [1]	
	
	 	 	 	 	 						ep	=	10-α	 	 	 	 	 	[2]	
	
where	x	and	α	are	the	selected	percentile	and	the	exponent	of	the	power	law	function,	
respectively.	The	cumulative	probability	was	calculated	from	the	function:	
	
	 	 	 	 	 𝑃 𝑥 = 	 $%&& ∝	 	 	 	 [3]	
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In	the	present	study,	the	top	0.01	percentile	was	selected	for	the	reasons	given	elsewhere	
(Rodríguez-Navarro	&	Brito,	2018b).	The	expected	frequency	of	papers	in	the	top	0.01%	of	
the	most	cited	publications	is	equal	to	the	cumulative	probability,	P(x),	multiplied	by	the	
number	of	publications.	This	cumulative	frequency	is	named	Ptop	0.01%	using	the	Leiden	
Ranking	notation	(Bornmann,	Wagner,	&	Leydesdorff,	2015;	Waltman	et	al.,	2012).	
	
It	is	worth	noting	that	the	three	parameters	are	highly	related	but	different.	The	ep	index	is	
both	percentile-	and	size-independent,	and	reveals	the	breakthrough	potential	of	the	
research	system	(Rodríguez-Navarro	&	Brito,	2018b).	The	other	two	parameters	depend	on	
the	selected	percentile;	the	probability	is	size	independent	and	the	cumulative	frequency	is	
size	dependent.	
	
2.2.	Topics	
	
The	purpose	of	this	study	was	to	investigate	the	country’s	research	performances	across	the	
world	in	biological	areas	focused	on	medicine	and	biotechnology.	These	two	areas	are	not	
independent;	for	example,	molecular	biology	or	microbiology	can	be	similarly	applied	two	
both	areas.	Therefore,	we	selected	a	set	of	medical	topics	and	another	set	of	biochemical	
and	biothechnology	research	areas,	maintaining	the	common	topics	in	only	one	of	the	two	
sets.	Furthermore,	it	has	been	shown	previously	that	country’s	research	performance	varies	
enormously	not	only	across	research	fields	(e.g.,	physics,	chemistry,	or	biology),	which	seems	
logical,	but	also	depending	on	the	research	activity	of	the	field,	(i.e.,	hot	or	quiescent	topics:	
Bonaccorsi,	2007;	Brito	&	Rodríguez-Navarro,	2018;	Rodriguez-Navarro	&	Narin,	2018;	
Sachwald,	2015).	Taking	this	into	consideration,	we	selected	research	topics	and	areas	that	
currently	are	highly	cited.	For	medical	research	we	selected	six	topics:	cancer,	CRISPR,	
microbiota,	stem	cells,	immunity,	and	inflammation;	for	biochemistry	and	biotechnology	we	
selected	four	WoS	research	areas:	biochemistry	and	molecular	biology,	biotechnology	and	
applied	biotechnology,	cell	biology,	and	microbiology.	The	searches	in	the	latter	WoS	areas	
specifically	excluded	the	selected	medical	topics	in	order	to	retrieve	two	independent	sets	of	
publications.	In	2014,	we	retrieved	148,375	and	76,299	publications	in	the	hot	medical	
topics	and	biochemical	research	areas,	respectively.	The	number	of	citations	of	the	most	
cited	papers	was	high	in	both	cases,	the	lowest	number	of	citations	of	publications	in	the	top	
1%	of	most	cited	papers	were	93	for	the	medical	topics	and	69	for	the	biochemical	and	
molecular	biology	areas	(counted	on	Feb	23,	2018).	Although	the	selected	topics	and	
research	areas	did	not	include	all	possible	topics	that	could	be	of	interest	for	this	study,	the	
high	number	of	retrieved	papers	indicates	that	they	constitute	a	large	representative	sample	
of	them.	
	
2.3.	Countries	
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We	divided	the	world	into	three	geographical	research	areas:	the	ERA	(European	Research	
Area),	the	USA,	and	Others	(i.e.,	all	countries	excluding	the	ERA	countries	and	the	USA;	all	
countries	means	the	50	most	productive	countries	in	2014).	These	geographical	areas	were	
analyzed	independently,	omitting	collaborative	publications	between	them.	The	eight	largest	
and	scientifically	most	active	countries	in	the	ERA:	Germany,	France,	UK,	Italy,	Spain,	
Sweden,	The	Netherlands,	and	Switzerland	were	also	studied.	In	Others,	we	selected	the	six	
most	active	countries	in	the	selected	research	topics	and	areas:	Australia,	Canada,	China,	
Japan,	South	Korea,	and	Taiwan.	In	some	cases	we	record	results	for	the	EU	excluding	the	UK	
in	order	to	cancel	out	the	dominant	role	that	Switzerland	and	the	UK	play	in	ERA	research	
(Rodríguez-Navarro	&	Brito,	2018b).	
	
In	the	15	selected	countries	we	retrieved	only	domestic	papers	(all	authors	in	the	same	
country	or	set	of	countries)	for	the	reasons	given	in	section	4.	Some	collaborative	
publications	between	two	countries	were	also	studied	to	complement	the	study	of	domestic	
papers.	
	
2.4.	Bibliometric	searches	
	
Bibliometric	searches	were	performed	in	the	Science	Citation	Index	Expanded	of	the	Web	of	
Science	Core	Collection	(WoS),	using	the	“Advanced	Search”	feature	and	retrieving	only	
publications	labeled	as	“Articles.”	For	highly	cited	medical	topics	we	used:	TS=(cancer	OR	
crispr*	OR	microbiota	OR	stem	cell*	OR	immunity	OR	inflamma*	NOT	statistics	NOT	trial	
NOT	survey),	and	for	biochemistry	and	biotechnology	we	used:	SU=((biochemistry	&	
molecular	biology	OR	biotechnology	&	applied	biotechnology	OR	cell	biology	OR	
microbiology)	NOT	(computer	science	OR	mathematical	&	computational	biology))	NOT	
TS=(cancer	OR	crispr*	OR	microbiota	OR	stem	cell*	OR	immunity	OR	inflamma*	OR	statistics	
OR	trial	OR	survey).	Searches	were	performed	between	February	23	and	March	5,	2018.	
Some	countries	were	analyzed	in	different	days	but	each	analysis	in	a	different	day	was	
complete	including	world	and	country	citation	distributions.	
	
3.	Results	
	
3.1.	Medicine	
	
To	obtain	a	first	overview	of	world	research	in	hot	medical	topics,	we	studied	the	evolution	
of	the	three	aforementioned	parameters	between	1984	and	2014	(Figure	2).	The	number	of	
publications	in	the	selected	medical	topics	increased	enormously	over	these	30	years,	from	
3,686	to	148,375	annual	publications.	Growth	in	the	USA	and	the	ERA	was	similar,	while	in	
Others	it	was	much	higher,	especially	over	the	last	10	years	(2004–2014).	Throughout	this	
time,	the	research	performance	in	the	USA,	as	revealed	by	the	ep	index	and	the	paper	
probability	of	reaching	the	top	0.01	percentile,	was	much	higher	than	in	the	ERA	and	Others.	
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The	performance	of	the	USA	was	already	the	best	in	1984	and	it	increased	over	time.	The	ep	
index	showed	a	clear	tendency	of	the	ERA	catching	up	with	the	USA	in	the	1984–1994	
period;	however,	this	tendency	decreased	in	the	1994–2004	period	and	disappeared	in	
2004–2014.	Even	in	1984–1994,	the	paper	probability	of	reaching	the	top	0.01	percentile	
showed	that	the	ERA	was	clearly	lagging	compared	to	the	USA.	This	apparently	contradictory	
trend	between	the	ep	index	and	paper	probability	of	reaching	the	top	0.01	percentile	was	
due	to	the	original	great	difference	between	the	USA	and	the	ERA,	and	the	mathematical	
relationship	between	both	parameters,	which	is	exponential	of	a	logarithm.	Because	of	the	
original	large	difference,	the	ERA	should	increase	its	ep	index	more	than	the	USA	to	decrease	
the	difference	in	paper	probability	of	reaching	the	top	0.01	percentile;	for	example,	if	the	
USA	(ep	≈	0.10)	increased	the	ep	index	by	10%	the	ERA	(ep	≈	0.06)	should	increase	it	by	25%	to	
similarly	increase	the	probability.	
	
			
	
Figure	2.	Evolution	of	research	performance	in	the	USA,	the	European	Research	Area	(ERA),	and	other	countries	
in	top	medical	topics	over	30	years.	Curves	are	drawn	to	guide	the	eye.	Symbols:	squares,	the	USA;	diamonds,	
the	ERA;	triangles,	other	countries.	
	
Due	to	the	large	increase	in	the	number	of	publications,	the	cumulative	frequency	of	
publications	in	the	top	0.01	percentile	(Ptop	0.01%)	increased	in	the	three	geographical	areas	
studied	here;	however,	because	of	the	higher	US	research	performance,	the	difference	
between	the	USA	and	both	the	ERA	and	Others	increased	permanently	over	the	30-year	
period.	
	
Next,	we	calculated	the	research	performance	parameters	for	individual	countries	(Table	1).	
The	countries	with	the	highest	ep	index	values	were	Switzerland	(0.15)	and	the	USA	(0.12),	
both	of	which	were	above	the	world	average.	All	the	other	countries	performed	worse	than	
the	global	average	(<	0.10);	the	ep	index	varied	from	approximately	0.08	in	the	UK,	
Netherlands,	Germany,	and	Sweden	to	less	than	0.05	in	South	Korea,	Japan,	and	Taiwan.	The	
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performance	of	the	EU	excluding	the	UK	was	similar	to	that	of	Canada	and	Australia.	Among	
the	four	biggest	EU	countries	(Germany,	Spain,	France,	and	Italy)	Germany	and	France	
performed	better	than	the	EU	excluding	the	UK.	The	probability	of	publishing	a	paper	in	the	
0.01	percentile	reflected	the	differences	in	the	ep	index,	and	the	expected	frequency	of	
papers	in	the	top	0.01%	of	the	most	cited	publications,	Ptop	0.01%,	reflected	both	the	
differences	in	the	ep	index	and	in	the	number	of	publications.	The	Ptop	0.01%	indicator	was	10-
fold	higher	in	the	USA	than	in	the	EU	excluding	the	UK	and	5-fold	higher	than	in	the	ERA.	
	
Table	1.	Research	performance	parameters	in	hot	medical	topics,	in	15	selected	
cases.	Publications	in	2014;	domestic	counts.	
Countries	 Number	of	
publications	
ep	index	 Paper	
probability	
for	top	0.01%	
P(top	0.01%)	
Switzerland	 734	 0.1479	 0.0004782	 0.3510	
USA	 28818	 0.1180	 0.0001936	 5.5778	
UK	 3398	 0.0822	 0.0000456	 0.1550	
Netherlands	 1721	 0.0814	 0.0000439	 0.0755	
Germany	 4817	 0.0806	 0.0000423	 0.2038	
Sweden	 1094	 0.0791	 0.0000392	 0.0429	
France	 3175	 0.0721	 0.0000270	 0.0856	
Canada	 2705	 0.0670	 0.0000202	 0.0546	
EU	w/o	UK	 27241	 0.0665	 0.0000196	 0.5331	
Australia	 2155	 0.0644	 0.0000172	 0.0370	
Spain	 2419	 0.0579	 0.0000113	 0.0272	
China	 23602	 0.0566	 0.0000103	 0.2426	
Italy	 4231	 0.0543	 0.0000087	 0.0369	
South	Korea	 5751	 0.0484	 0.0000055	 0.0315	
Japan	 7925	 0.0470	 0.0000049	 0.0387	
Taiwan	 2682	 0.0331	 0.0000012	 0.0032	
	
	
To	further	investigate	the	dominant	role	of	USA	research,	we	calculated	the	performance	
parameters	of	collaborations	between	the	USA	and	others	countries	(we	actually	studied	co-
authorship,	according	with	Katz	&	Martin,	1997).	The	results	summarized	in	Table	2	reveal	
that	any	country	collaborating	with	the	USA	substantially	improved	its	ep	index	and	paper	
probability	of	reaching	the	top	0.01	percentile.	However,	the	increase	in	this	probability	was	
irregular;	for	example,	it	amounted	38-fold	in	Germany	but	only	2.7-fold	in	Switzerland.	The	
increase	of	the	probability	was	so	high	that	although	the	number	of	collaborative	papers	was	
much	lower	than	the	number	of	domestic	papers,	the	collaborative	Ptop	0.01%	indicator	was	
much	higher	than	for	domestic	papers—with	the	exception	of	Switzerland.	With	reference	
to	domestic	papers,	the	collaboration	between	Switzerland	and	Germany	increased	11-fold	
the	probability	for	a	paper	from	Germany	to	reach	the	0.01	percentile	but	there	was	no	
increase	for	Switzerland’s	papers.	
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Table	2.	Research	performance	parameters	in	hot	medical	topics,	in	seven	cases	of	research	collaborations	
between	two	countries.	Publications	in	2014.	
Countries	 Number	of	
publications	
ep	index	 Paper	probability	
for	top	0.01%	
Ptop	0.01%	
Germany	and	USA	 767	 0.2001	 0.001604	 1.2303	
Canada	and	USA	 1059	 0.1919	 0.001356	 1.4365	
Switzerland	and	USA	 206	 0.1904	 0.001315	 0.2708	
Japan	and	USA	 696	 0.1442	 0.000433	 0.3013	
China	and	USA	 3481	 0.0990	 0.000096	 0.3343	
South	Korea	and	USA	 774	 0.0846	 0.000051	 0.0397	
Switzerland	and	Germany	 261	 0.0812	 0.000044	 0.0114	
	
Apparently,	the	USA	also	benefited	from	some	of	these	collaborations,	especially	with	
Germany,	Canada,	and	Switzerland,	as	they	increased	the	domestic	USA	ep	index;	however,	
this	is	not	the	best	explanation	as	we	discuss	in	section	4.	
	
3.2.	Biochemistry	and	biotechnology	
	
In	this	case,	the	evolution	of	the	number	of	publications	over	30	years	was	substantially	
different	from	that	observed	in	hot	medical	topics	(compare	Figures	2	and	3).	The	number	of	
USA	and	ERA	publications	increased	in	the	1984–1994	period	and	remained	constant	or	
decreased	after	this	time.	Only	Others	retained	a	permanent	growth	throughout	the	30-year	
period.	It	is	worth	noting	that	these	searches	were	performed	using	research	areas	that	
were	made	up	by	a	collection	of	journals.	Therefore,	the	differential	growth	in	the	number	
of	papers	between	areas	is	highly	dependent	on	the	inclusion	of	new	journals	in	them	and	
changes	in	topic	preferences	by	researchers.	
	
			
	Figure	3.	Evolution	of	research	performance	in	the	USA,	the	European	Research	Area	(ERA),	and	other	countries	
in	biochemistry	and	biotechnology	over	30	years.	Curves	are	drawn	to	guide	the	eye.	Symbols:	squares,	the	USA;	
diamonds,	the	ERA;	triangles,	other	countries.	
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Despite	the	differences	in	the	evolution	of	the	number	of	publications	in	the	hot	medical	
topics	and	biochemistry	and	biotechnology,	the	evolution	of	the	ep	index	in	these	two	
research	fields	showed	the	similarity	of	small	changes,	positive	evolution	in	the	USA,	and	
neutral	or	negative	evolution	in	the	other	two	geographical	areas.	The	other	size	
independent	indicator,	the	probability	that	a	paper	reach	the	top	0.01	percentile,	evolved	as	
the	ep	index	because	it	is	mathematically	linked	to	it.	As	observed	in	hot	medical	topics,	also	
in	biochemistry	and	biotechnology,	the	performance	of	the	USA	was	already	the	best	in	
1984	and	it	increased	over	time.	
	
Table	3.	Research	performance	parameters	in	Biochemistry	and	Biotechnology	research	
areas,	in	15	selected	cases.	Publications	in	2014;	domestic	counts.	
Country	 Number	of	
publications	
ep	index	 Paper	
probability	
for	top	0.01%	
P(top	0.01%)	
USA	 12542	 0.1323	 0.0003068	 3.847	
UK	 1795	 0.1317	 0.0003009	 0.540	
Switzerland	 499	 0.1219	 0.0002210	 0.110	
Netherlands	 652	 0.1208	 0.0002132	 0.139	
Sweden	 470	 0.1011	 0.0001043	 0.049	
Australia	 936	 0.0938	 0.0000775	 0.073	
Germany	 2782	 0.0827	 0.0000468	 0.130	
Canada	 1557	 0.0771	 0.0000354	 0.055	
China	 10991	 0.0740	 0.0000301	 0.330	
France	 1793	 0.0677	 0.0000211	 0.038	
EU	w/o	UK	 15212	 0.0662	 0.0000192	 0.292	
Italy	 1563	 0.0534	 0.0000081	 0.013	
Spain	 1638	 0.0505	 0.0000065	 0.011	
South	Korea	 2379	 0.0489	 0.0000057	 0.014	
Taiwan	 895	 0.0418	 0.0000031	 0.003	
Japan	 3597	 0.0375	 0.0000020	 0.007	
	
The	analysis	of	countries	(Table	3)	showed	that	the	USA,	the	UK,	Switzerland,	and	the	
Netherlands	performed	clearly	better	than	the	world	average	(ep	index	>	0.1).	The	
performance	by	Sweden	and	Australia	was	approximately	equal	to	the	world	average	(ep	
index	=	0.1),	and	all	the	other	countries	showed	worse	performances	(ep	index	<	0.1).	The	EU	
excluding	the	UK	showed	rather	a	poor	performance	(ep	index	=	0.07).	As	with	hot	medical	
topics,	South	Korea,	Taiwan	and	Japan	showed	the	lowest	performances,	which	were	
considerably	below	the	average	global	performance.	The	probability	of	publishing	a	paper	in	
the	0.01	percentile	reflected	the	differences	in	the	ep	index	and	the	Ptop	0.01%	reflected	both	
the	differences	in	the	ep	index	and	in	the	number	of	publications.	The	Ptop	0.01%	indicator	was	
12-fold	higher	in	the	USA	than	in	the	EU	excluding	the	UK	and	4-fold	higher	than	in	the	ERA.	
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Table	4.	Research	performance	parameters	in	biochemistry	and	biotechnology	research	areas,	in	seven	
research	collaborations	between	two	countries.	Publications	in	2014	
Countries	 Number	of	
publications	
ep	index	 Paper	probability	
for	top	0.01%	
Ptop	0.01%	
Switzerland	and	USA	 112	 0.2600	 0.0045709	 0.512	
Japan	and	USA	 285	 0.1654	 0.0007482	 0.213	
Germany	and	USA	 409	 0.1654	 0.0007482	 0.213	
Canada	and	USA	 403	 0.1438	 0.0004278	 0.172	
Switzerland	and	Germany	 127	 0.1303	 0.0002887	 0.037	
China	and	USA	 1403	 0.1157	 0.0001791	 0.251	
South	Korea	and	USA	 329	 0.1062	 0.0001273	 0.042	
	
Once	again,	collaboration	with	the	USA	substantially	improved	the	research	performance	of	
all	countries	tested	(Table	4);	the	increase	in	paper	probability	of	reaching	the	top	0.01	
percentile	was	very	irregular.	For	example,	it	was	more	than	300-fold	higher	for	Japan.	For	
Switzerland	and	Germany	the	collaboration	with	the	USA	increased	the	top	0.01%	
probability	by	21-	and	16-fold,	respectively.	The	collaboration	between	Switzerland-
Germany	increased	6-fold	the	top	0.01%	probability	of	Germany	but	insignificantly	the	
probability	of	Switzerland.	Although	the	number	of	publications	resulting	from	these	
collaborations	was	lower	than	the	number	of	domestic	papers,	the	cumulative	frequency	of	
publications	in	the	top	0.01	percentile	was	higher	in	collaborations.	Only	in	Germany	did	the	
improved	research	performance	not	compensate	for	the	decreased	number	of	publications.	
	
Apparently,	the	USA	also	benefited	from	some	of	these	collaborations,	especially	with	
Switzerland,	as	they	increased	the	domestic	USA	ep	index;	however,	as	aforementioned,	this	
is	not	the	best	explanation	as	we	discuss	in	section	4.	
	
4.	Discussion	
	
To	quantify	research	performance	in	countries	and	institutions,	we	have	used	three	
parameters	derived	from	citation	distributions:	the	ep	index,	which	reveals	the	breakthrough	
potential,	the	probability	for	a	country	publication	to	reach	the	global	top	0.01	percentile,	
and	the	cumulative	frequency	of	publications	in	this	percentile.	As	explained	previously,	
these	parameters	are	mathematically	calculated	from	the	country’s	distribution	of	
publications	in	the	global	publication	percentiles	based	on	citations.	The	ep	index	is	
percentile-independent	while	the	other	two	parameters	require	a	specific	percentile	to	be	
selected	(Rodríguez-Navarro	&	Brito,	2018b).		
	
The	rational	behind	the	method	of	selecting	a	low	percentile	to	estimate	research	
performance	is	the	assumption	that	the	number	of	highly	cited	publications	correlates	with	
the	number	of	discoveries	or	breakthroughs	that	a	research	system	produces	(Brito	&	
Rodríguez-Navarro,	2018	and	references	therein).	This	number	of	important	discoveries	or	
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breakthroughs	that	boost	science	and	breakthrough	innovations	is	very	low,	as	is	the	
number	of	the	highly	cited	papers	that	report	these	achievements.	In	consequence	research	
performance	has	to	be	evaluated	at	a	low	percentile.	The	low	number	of	breakthrough	
papers	precludes	counting	these	papers;	however,	the	probability	of	its	achievement	can	be	
calculated	(equation	[1]).	It	is	worth	highlighting	that	the	correlation	between	important	
achievements	and	the	high	number	of	citations	does	not	imply	that	one	of	the	parameters	
measures	the	other	and	that,	therefore,	it	cannot	be	applied	to	low	aggregation	levels	such	
as	individual	researchers	or	small	groups	(Allen,	Jones,	Dolby,	&	Walport,	2009;	Ruiz-Castillo,	
2012;	van-Raan,	2005).	In	conclusion,	the	probability	that	a	paper	published	in	a	country	
reaches	a	low	percentile	equates	to	the	country’s	probability	of	achieving	important	
breakthroughs	or	discoveries	of	a	similar	frequency.	
	
The	selection	of	the	top	0.01	percentile	implies	that	in	the	topics	and	research	areas	studied,	
which	produce	approximately	150,000	and	80,000	annual	publications,	respectively,	a	total	
of	15	and	8	important	discoveries	or	breakthroughs	would	be	expected	per	year,	which	
seems	reasonable	(Bornmann,	Ye,	&	Ye,	2018).	Considering	less	important	discoveries	or	
breakthroughs	a	higher	top	percentile	would	be	used,	e.g.,	0.1	or	even	1.0.	This	less	
stringent	percentile	selection	would	blur	the	country	differences	revealed	by	the	probability	
and	expected	frequency	at	the	top	0.01	percentile;	however,	it	would	not	affect	the	ep	index.	
	
The	hot	medical	topics	and	biochemical	areas	we	study	here	are	quite	different	from	the	fast	
evolving	hot	technological	topics	we	studied	previously	(Rodríguez-Navarro	&	Brito,	2018b),	
which	belong	to	physical	and	chemical	fields.	However,	in	both	cases,	citation	levels	are	
similarly	high,	which	reveals	high	interest	of	researchers	for	these	research	fields.	This	
similarity	may	have	been	the	reason	why	country	research	assessments	in	the	two	quite	
different	scientific	fields	show	many	coincidences;	however,	for	reasons	we	have	not	
investigated	they	also	show	notable	differences.	The	coincidence	is	the	large	advantage	of	
the	USA	over	the	ERA,	and	the	difference	is	that	the	Others	are	approaching	to	the	USA	in	
terms	of	the	expected	number	of	very	highly	cited	publications	in	hot	technological	but	not	
in	hot	medical	and	biochemical	topics.	Regarding	the	number	of	important	discoveries	and	
breakthroughs,	our	results	suggest	that	the	USA	produces	approximately	40%	of	them	in	hot	
technological	topics	(fast	evolving	topics,	Table	3,	in	Rodríguez-Navarro	&	Brito,	2018b)	and	
approximately	80%	in	the	biological	fields	studied	here	(Figures	2	and	3).	However,	it	is	
important	to	note	that	this	remarkable	high	share	of	production	in	the	biological	fields	was	
obtained	when	publishing	a	quarter	of	the	global	number	of	papers.	The	biochemical	and	
biotechnological	research	areas	studied	here	are	not	as	highly	cited	as	the	hot	medical	
topics;	however,	they	are	still	highly	cited,	and	the	results	are	not	largely	different	from	
those	in	hot	medical	topics	(compare	Figures	2	and	3).	
	
Further	studies	are	necessary	to	determine	the	relationship	between	R&D	investments,	the	
total	number	of	publications,	and	the	indicators	used	in	this	study.	In	any	case,	the	large	
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differences	across	countries	in	research	performance	attending	to	the	probability	of	a	paper	
reaching	the	top	0.01	percentile	(Tables	1	and	3)	strongly	suggest	that	knowledge	
production	depends	more	on	research	performance	than	on	the	total	number	of	
publications	or	R&D	investments	and	capital.	Therefore,	the	use	of	the	last	two	parameters	
in	econometric	studies	is	necessarily	misleading,	because	it	is	equivalent	to	considering	a	
constant	research	performance	across	countries.	We	agree	with	the	notion	that	“the	
benefits	of	scientific	discovery	have	been	heavy-tailed”	(Press,	2013,	p.	822)	but	this	and	
previous	(Rodríguez-Navarro	&	Brito,	2018b)	studies	show	that	the	heavy-tailed	discoveries	
vary	enormously	across	countries.	Therefore,	it	can	be	concluded	that	the	benefits	of	
research	are	likely	to	be	highly	variable	across	countries	and	that	they	can	be	high	or	low	
independently	of	R&D	investments	or	capital,	at	least	in	economically	advanced	countries.	
	
Here	we	have	studied	the	research	performance	of	the	ERA,	the	EU,	and	other	countries	
counting	only	domestic	papers	(i.e.,	excluding	collaborations	with	external	countries).	This	
method	does	not	measure	the	total	scientific	production	of	the	research	actors;	however,	in	
our	opinion,	it	is	the	only	method	that	can	reveal	the	actual	research	performance	level	of	a	
country	or	group	of	countries.	Many	arguments	have	been	given	in	support	of	different	
counting	methods	(Gauffriau,	2017),	but	no	method	has	been	developed	or	can	be	
developed	to	distribute	unbalanced	knowledge	contributions	among	collaborating	countries	
in	unbalanced	international	collaborations	(Zanotto,	Haeffner,	&	Guimaraes,	2016).	For	
example,	the	data	in	Tables	1–4	strongly	suggest	that	considering	collaborations	between	
USA	and	China	would	mistakenly	improve	the	research	performance	of	Chinese	researchers.	
It	is	worth	noting	that	this	apparent	improvement	of	research	performance	that	obtains	a	
partner	with	a	low	research	performance	does	not	occur	if	the	partner	is	a	highly	
competitive	country	such	as	Singapore	in	fast	evolving	technological	topics	(Rodríguez-
Navarro	&	Brito,	2018b).	
	
Another	issue	is	the	apparent	improvement	in	research	performance	that	also	occurs	for	the	
USA	in	collaborative	papers;	collaboration	with	Germany,	Canada,	or	Switzerland	increased	
the	USA	ep	index	by	1.6-fold	in	hot	medical	topics	(Tables	1	and	2)	and	2.0-fold	in	the	
collaboration	with	Switzerland	in	biochemistry	and	biotechnology	(Tables	3	and	4).	However,	
this	increase	might	not	imply	a	real	increase	of	the	breakthrough	potential	of	the	USA.	The	
most	probable	reason	for	this	increase	is	that	these	international	collaborations	do	not	occur	
at	random	with	all	USA	research	institutions	but	occurs	preferentially	with	top	institutions	in	
which	the	ep	index	is	much	higher	than	the	USA	ep	index,	which	is	a	national	average.	For	
example,	the	ep	index	of	the	Massachusetts	Institute	of	Technology	(MIT)	or	Harvard	
University	in	the	two	research	fields	studied	here	is	approximately	0.3	(unpublished	results),	
which	is	considerably	higher	than	those	measured	in	the	aforementioned	collaborations	
between	USA	and	other	country.	It	is	hard	to	believe	that	collaborations	between	MIT	or	
Harvard	University	and	Switzerland	or	Germany	would	improve	the	ep	index	of	MIT	and	
Harvard	University.	
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International	collaborations	(actually	co-authorships	here,	according	with	Katz	&	Martin,	
1997)	are	numerous	(Leydesdorff,	Wagner,	Park,	&	Adams,	2013;	Wagner,	Park,	&	
Leydesdorff,	2015)	and	raise	a	complex	problem	in	research	evaluation	and	policy.	This	
problem	does	not	fall	under	the	scope	of	this	study	and	the	conclusions	above	apply	
exclusively	to	the	research	topics	and	the	research	fields	studied	here.	
	
On	average,	the	probability	that	a	paper	reaches	the	top	0.01	percentile	is	much	lower	when	
the	paper	is	published	in	EU	continental	countries	than	when	it	is	published	in	the	USA	
(approximately	10-	and	16-fold	in	hot	technological	topics	and	biochemistry	and	
biotechnology,	respectively).	Aside	from	the	discussion	of	whether	this	countries’	ratio	
accurately	reflects	the	ratio	for	the	achievement	of	discoveries	and	breakthroughs,	the	
empirical	fact	cannot	be	denied	and	raises	the	question	of	why	EU	research	is	scarcely	
successful	in	publishing	highly	cited	papers.	The	ep	index	in	the	most	successful	countries	in	
continental	Europe,	Switzerland	and	the	Netherlands,	is	similar	to	that	of	the	USA;	however,	
there	are	differences	that	raise	some	doubts	about	the	comparison.	Switzerland	and	the	
Netherlands	are	small	countries	with	a	low	number	of	research	universities	that	maintain	a	
high	level	of	research	performance.	In	contrast,	due	to	its	size,	the	USA	has	many	
universities.	In	top	USA	universities	the	ep	index	is	around	0.3	(unpublished	results);	
however,	at	the	end	of	the	ranking	the	figures	might	be	100-fold	lower.	
	
Table	5.	Ptop	0.01%	per	million	inhabitants	across	countries	
Country	 Hot	medical	topics	 Biochem	&	Biotechnol	
Switzerland	 0.04387	 0.01379	
USA	 0.01743	 0.01202	
Netherlands	 0.00444	 0.00818	
Sweden	 0.00429	 0.00490	
Germany	 0.00249	 0.00159	
UK	 0.00235	 0.00818	
Australia	 0.00154	 0.00302	
Canada	 0.00148	 0.00149	
France	 0.00132	 0.00058	
Spain	 0.00065	 0.00025	
Italy	 0.00062	 0.00022	
South	Korea	 0.00062	 0.00027	
Japan	 0.00030	 0.00006	
China	 0.00017	 0.00024	
Taiwan	 0.00013	 0.00011	
	
	
From	the	point	of	view	of	the	economy	of	a	country,	it	seems	logical	that	for	a	similar	effect	
bigger	countries	will	need	higher	numbers	of	scientific	breakthroughs.	To	relate	country	size	
and	research	success,	the	cumulative	frequency	for	the	top	0.01	percentile	(Ptop0.01%)	can	be	
divided	by	the	GDP	or	the	number	of	inhabitants.	Using	the	latter	normalization	in	hot	
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medical	topics	(Table	5),	the	first	country	is	Switzerland,	very	prominent,	and	the	second	
country	is	the	USA;	Netherlands	and	Sweden	are	the	next	two	countries.	In	biochemistry	and	
biotechnology,	again	the	first	two	countries	are	Switzerland	and	the	USA.	The	UK	and	
Netherlands	are	the	next	two	countries		
	
Irrespective	of	the	measurement	method,	it	is	evident	that	the	four	biggest	continental	EU	
countries	keep	a	low	research	performance	if	the	USA	is	taken	as	a	reference,	which	raises	a	
question	about	the	causes.	A	key	clue	to	answering	this	question	might	be	that	the	greater	
differences	occurs	in	fast	evolving	research	topics	(Bonaccorsi,	2007;	Rodríguez-Navarro	&	
Brito,	2018b;	Rodriguez-Navarro	&	Narin,	2018;	Sachwald,	2015)	that	arouse	greater	interest	
in	society	and	researchers.	It	is	remarkable	that	in	the	WoS	research	areas	“plant	sciences”	
and	“physiology”	the	USA	and	the	EU	are	similarly	successful.	The	ep	index	has	not	been	
calculated	in	these	areas,	but	the	similarity	of	the	double	rank	plots	(Figures	1	and	2	in	
Rodríguez-Navarro	&	Brito,	2018a)	allows	the	prediction	of	very	similar	ep	index	values.	This	
situation	is	puzzling,	suggesting	differences	in	researchers’	motivations.	For	example,	the	
mechanisms	of	plant	innate	immunity,	which	is	one	of	hundreds	of	plant	responses	that	
have	so	far	not	had	societal	relevance,	is	a	“hot	research	front”	in	the	EU	(Rodríguez-Navarro	
&	Brito,	2018b)	while	human	cancer	or	immunity,	where	societal	relevance	is	
unquestionable,	EU	research	is	not	successful	(Table	1).	
	
5.	Conclusions	
	
Citation	distributions	can	be	used	to	reveal	the	scientific	competence	and	efficiency	of	
countries.	These	characteristics	can	be	quantified	through	the	probability	of	publishing	a	
paper	surpassing	a	certain	high	level	of	citations,	which	is	a	rare	event	like	breakthroughs	
and	discoveries.	The	high	variability	of	this	probability	across	economically	advanced	
countries	indicates	that	successful	research	depends	on	intrinsic	characteristics	of	research	
systems	that	are	currently	unknown.	A	gaming	simile	would	be	that,	for	an	unknown	reason,	
throwing	a	seven	using	two	dice	had	a	probability	of	0.17	in	the	USA	and	10-fold	less	in	the	
EU.	
	
If	researcher	curiosity	is	the	driving	force	behind	discoveries,	it	seems	that	researchers	in	
different	countries	have	curiosities	of	different	scientific	and	societal	relevance.	
Furthermore,	our	30-year	study	of	the	evolution	of	the	scientific	performance	of	the	USA	
and	the	EU	suggests	that	scientific	competence	and	efficiency	is	an	intrinsic	characteristic	of	
old	research	systems	that	does	not	change	easily.	In	any	case,	a	Mathew	effect	seems	to	
exist,	which	makes	the	strong	USA	research	to	evolve	stronger	while	the	weak	EU	research	
undergoes	minimal	positive	or	negative	fluctuations.	
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